Group items tagged

Department of Health and Social Care (DHSC) has increased the rate of discount deduction for generics from 17.52 per cent to 20 per cent. The Drug Tariff for April 2023 will contain changes to the discount deduction arrangements for pharmacy contractors, which will include- all concession lines to be considered as Group Items for Discount Not Deducted i.e. DND or zero discount (ZD) items; and rate of discount deduction for generics to increase from 17.52% to 20% The Pharmaceutical Services Negotiating Committee (PSNC) and DHSC agreed on the changes for all concession lines to be considered as Group Items for Discount Not Deducted. Therefore from 1 April 2023, a new category will be introduced into Part II of the Drug Tariff 'Drugs for which discount is not deducted'. However, the committee had rejected the changes in the rate of discount deduction for generics. It said, "Following pressure from NHS England, Ministers have now chosen to impose changes to the previously agreed discount deduction arrangements, which come into effect from 1 April, and will be kept under review."

The Department of Health and Social Care (DHSC) has introduced new arrangements for the application of discount deduction to community pharmacy payments which will be implemented in six financial quarters beginning in October 2022 and concluding in January 2024. Under the new discount deduction system, the current single scale will be split into three groups: one each for generic medicines, branded medicines, and appliances. Separate fixed deduction rates have been determined for each group. This will provide all pharmacies the same rates of deduction applied to their reimbursement for the three different groups, regardless of the total value of that reimbursement. Fin McCaul, PSNC member and independent community pharmacy contractor, said: "The discount deduction scale has been a point of contention for contractors for many years, and PSNC has long been pushing to remedy this. "The incoming changes are designed to both improve equity of access to margin and manage the distortions presented by branded medicines, which just don't have the same level of discount available as generics.

The Pharmaceutical Services Negotiating Committee (PSNC) has developed a webtool to help community pharmacy contractors estimate the impact on their payments under the new discount deduction system. The calculator aims to illustrate the changes to discount deduction that a pharmacy could experience during the transition to the new arrangements from October 2022 to January 2024, when the new system will be fully in place. PSNC's calculator requires contractors to input information about their individual pharmacy dispensing mix (i.e. split of reimbursement by appliances, brands and generics) to provide an estimate for the level of impact the new discount deduction system will have. "The impact on individual pharmacies cannot be estimated without using dispensing mix data, meaning that any estimates which do not take this into account will not be reliable," said PSNC. For years many contractors have been frustrated by how discount is applied to their accounts and have often raised concerns about the blanket nature of its application to PSNC.

The Pharmaceutical Services Negotiating Committee (PSNC)'s director of pharmacy funding Mike Dent and Jack Cresswell, its funding strategy manager, will be hosting a webinar about changes to the discount deduction system on Wednesday 12th October at 7.30pm. The discount deduction scale has been a point of contention for community pharmacy contractors for many years, and PSNC has been pushing to remedy this. "The changes will lead to a levelling out for all pharmacies, with the impact on individual contractors varied due to their unique dispensing mix. We have been developing a series of resources about the changes, including an explanatory briefing, FAQs and an impact calculator. Our latest resource comes in the form of a webinar that aims to explain the new arrangements and the transition period in more detail," said PSNC.

FreeStyle Libre 3 Sensors and Budesonide 500microgram orodispersible tablets sugar free have been included in the Drugs for which Discount is Not Deducted (DND) list (Part II of the Drug Tariff) from January 2024, according to Community Pharmacy England (CPE). Following applications made by CPE on behalf of pharmacy contractors, the Department of Health and Social Care (DHSC) agreed to give DND status to these products to ensure that "pharmacies are not faced with dispensing these sensors at a loss." Updated monthly by the DHSC, Part II of the Drug Tariff includes grouped and individual items. Recently launched by Abbott Diabetes Care Ltd, FreeStyle Libre 3 Sensors have also been added to the Appliances section in Part IXA of the January 2024 Drug Tariff. As the sensors can only be ordered by pharmacies directly from the manufacturer without any discount, CPE requested the DHSC to exempt this appliance from any discount deduction.

The regulators have added 10 new products to the 'Drugs for which Discount is Not Deducted' (DND) list from Thursday (01 June). Community Pharmacy England on behalf of its members had made further applications to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), resulting in the inclusion of 10 new products in the DND. More than 610 products are granted DND status following checks made by Community Pharmacy England's dispensing & supply team over the past 3 years to ensure fair reimbursement for our members. The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the 'Group Items' heading are not listed again individually in Part II. "We will continue our work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual item' criteria and make applications to NHSBSA and DHSC, on behalf of our members accordingly," said Community Pharmacy England.

Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social Care (DHSC). This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating Committee. The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount deduction scale will no longer apply from July 2022: Fludrocortisone 50micrograms/5ml oral suspension (Group) Lorazepam 1mg/5ml oral suspension (Group) Lorazepam 500micrograms/5ml oral suspension (Group) Zopiclone 3.75mg/5ml oral solution (Group) Zopiclone 7.5mg/5ml oral solution (Group) GA explore5 oral powder 12.5g sachets HCU explore5 oral powder 12.5g sachets MSUD explore5 oral powder 12.5g sachets TYR explore5 oral powder 12.5g sachets The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.

Wheelchairs - What to Consider Before You Buy

Electric wheelchairs are the correct decision for somebody that comes up short on the abdominal area quality important to utilize a manual wheelchair. Here you can find out about the kinds of seats accessible and the interesting points previously you purchase.

Fixed footrest wheelchair



The manual seat is presumably the correct decision for somebody that will just need it for a brief time frame, despite the fact that offering an utilized electric wheelchair is less demanding than offering a manual. The distinction in cost is noteworthy. Power wheelchairs cost three to four times more than manuals.

Obviously, control seats fluctuate incredibly in cost and not just on account of configuration focal points or highlights. The maker's recommended retail cost is now and then four fold the amount of as what a discounter charges.

When you choose the highlights you require, it is a smart thought to do some relative shopping. The web has made it conceivable to effortlessly look at results of numerous types.

Weight is an imperative thought. Your weight and the heaviness of the seat should both be considered.

Standing Wheelchairs Paraplegic

Buy our Mung Beans Seed for Sprouting and daal at reasonable price. The seeds are natural, full of protein. Get here best offers and discounts on Mung Beans green seeds. Shop online now.

The government has launched a new 'Better Health' campaign to help people working towards healthier weight and reduce the risk of being hospitalised with Covid-19. The campaign launched in partnership with 15 weight management and physical activity partners will provide both free and discounted offers for weight management. Public health minister Maggie Throup said the campaign will focus on improving adults' health and help them to achieve a healthier weight. It will also include focus on the risk of serious diseases such as type 2 diabetes, heart disease and up to 12 types of cancer, to reducing the probability of hospitalisation with Covid-19. Besides highlighting these health conditions, the campaign will emphasise how these could be prevented by losing excess weight.

To provide a portable access of Pharmacy Support and Advice Service to pharmacists and technicians, the National Pharmacy Association (NPA) has launched an 'Associate Pharmacist' subscription. The service, comprising priority news-feed and email alerts, also includes NPA Learn - the association's Learning and Development hub. The offering to associates includes an annual online flu refresher or discounted full face-to-face vaccination training programme. NPA director of membership, Simon Tebbutt, said: "Associate Pharmacist is an offer to individuals, not to pharmacy businesses. We find that many pharmacists and technicians come into contact with NPA resources and like them, experiencing their quality as they move from pharmacy to pharmacy, either as a locum or as part of their career-building.

The Department of Health and Social Care's (DHSC) response to the 2019 consultation on community pharmacy drug reimbursement reform has paved the way for the second phase of consultation with the pharmacy negotiator. The second round of the consultation will focus on eight proposals: Changes to the way Category A prices are set Changes to how medicine margin is distributed in Category M drugs Changes to how Category C prices are set for drugs with multiple suppliers Inclusion of non-medicinal products in the Drug Tariff Changes to the way prices of drugs in non-Part VIIIA are set Changes to arrangements for reimbursement and procurement of 'specials' Changes to reimbursement of generically prescribed drugs and appliances dispensed as 'specials' Changes to the discount deduction scale The Pharmaceutical Services Negotiating Committee has been discussing these proposals with the DHSC and the outcome was featured in the final package of the 'Community pharmacy in 2016/17 and beyond' document.

Walgreens Boots Alliance, the American owner of Boots UK, could risk losing billions after a private equity firm interested in buying its UK high street pharmacy chain valued the retailer at a steep discount, The Telegraph reported on Monday (April 11). "Buyout funds CVC and Bain indicated that they were willing to pay just £4bn for the business," the newspaper said, adding that "the consortium bowed out of the running" in March. The US retail giant Walgreens, which acquired Boots in 2014 for £9bn, has put a £7bn price tag on the UK pharmacy retail chain after selling its wholesale arm, Alliance Healthcare, last year. Citing city sources, the newspaper said the low valuation of the pharmacy multiple was "significant" because CVC's UK operations were led by Dominic Murphy, a Walgreens board member involved with Boots for 15 years. "He (Murphy) knows where the bodies are buried," the newspaper quoted one City source as stating. A spokesperson for Boots confirmed that CVC and Bain never lodged a formal offer for the company.

The Department of Health and Social Care (DHSC) has added further 28 new products to the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II of the Drug Tariff from 1 August 2022. PSNC said, "It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual item' criteria and make applications to NHSBSA and DHSC, accordingly." A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.

In partnership with Oxford University Press, the Royal Pharmaceutical Society (RPS) has launched the 'RPS Pharmacy and Pharmacology' reports. RPS Pharmacy and Pharmacology Reports is a new, fully open access journal and the sister journal to Journal of Pharmacy & Pharmacology. The journal is edited by Professor Dennis Douroumis, professor in Pharmaceutical Technology and Process Engineering at the University of Greenwich. RPS said: "The journal aims to create a truly interdisciplinary forum for members of the pharmacy, pharmacology, chemistry, biochemistry, physiology, and microbiology communities alike to come together to develop life-changing medicines of the future. The journal prioritises scientifically sound results from pharmacy and pharmacology researchers across the world." The journal operates a rapid review and publication process to ensure impactful research is disseminated as quickly as possible. All RPS members are eligible to receive a 20 per cent discount on the article processing charge.

The new deal struck by the NHS will enable provision of a life-saving treatment for babies and young children who suffer with a rare and fatal genetic disease, metachromatic leukodystrophy (MLD). The revolutionary gene therapy treatment, known by its brand name Libmeldy, is used to treat MLD, which causes severe damage to the child's nervous system and organs, leading to a life expectancy of just five to eight years. Having a reported list price of more than £2.8 million, it is the most expensive drug in the world, but can now be offered to young patients on the NHS in England after the health service negotiated a significant confidential discount. the drug works by removing the patient's stem cells and replacing the faulty gene that causes MLD before then re-injecting the treated cells into the patient. The most common form of MLD usually develops in babies younger than 30 months and can cause loss of sight, speech and hearing, as well as difficulty moving, brain impairment, seizures, and eventually death.

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

British pharmacies and slimming clinics are reducing prices for weight-loss drugs Wegovy and Mounjaro in a competitive bid to win patients. Both Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (Tirzepatide) injection drugs are cleared for weight loss in combination with a reduced-calorie diet and increased physical activity. Wegovy was launched in the UK market in September, with Mounjaro following in February. Initially designed for treating type 2 diabetes, the drugs have been found to also induce weight loss by suppressing appetite and decelerating digestion. As reported by Reuters, Simple Online Pharmacy has further reduced the price of starter doses of Mounjaro to £149 for a one-month supply. In February, the price was cut to £159 ($198) from £179. Additionally, the pharmacy on Monday discounted the higher Mounjaro strengths that patients take later.

The UK GDP Association has been established as a non-profit organisation, operating as a Community Interest Company (CIC), with a focus on providing a broader support network, particularly for small and medium business enterprises and pharmacy wholesalers. In addition to delivering commercially viable Good Distribution Practice (GDP) consultancy services for simple models with smaller budgets, the association aims to function as a networking platform for Responsible Persons in the UK. As members of the association, companies and individuals can gain multiple benefits that will add value to their business through access to knowledge, discounted training, consultancy services, audit and inspection support, as well as resources like document templates for risk assessments, CAPA, deviations, and more. Moreover, members can enjoy the benefit of a like-minded support network via a dedicated GDP community hub, providing a platform for discussions, seeking advice, and fostering new relationships. "Our mission is to ensure that patient safety, GDP compliance, and excellent quality is paramount in all organisations, regardless of budget," the company said.